Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of belinostat and to see how
well it works in treating patients with liver cancer that cannot be removed by surgery.
Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth